Cidara Therapeutics announced that it has selected its first oncology drug-Fc conjugate, DFC, candidate from the company’s Cloudbreak platform: CBO-212, targeting CD73. "We are excited to start the new year by announcing CBO-212 as our first oncology DFC, marking a significant inflection point for Cidara and our Cloudbreak platform," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "With our Cloudbreak oncology program we seek to develop a new generation of immunotherapies, and our CBO-212 DFC is a first-in-class CD73 inhibitor that combines the strengths of small molecules and monoclonal antibodies targeting CD73. We look forward to advancing CBO-212 through IND enabling studies and providing updates on its progress in leading conferences as we continue to generate more data."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CDTX:
- Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform
- Cidara Therapeutics announces issuance of first U.S. patent for CD388
- Cidara Therapeutics Announces Issuance of First U.S. Patent for CD388
- Cidara announces two proxy firms recommend vote “FOR” reverse stock split
- Cidara Therapeutics, Melinta announce publication on ReSTORE trial of rezafungin